Related Experiment Video
Updated: Aug 14, 2026
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Advances in the treatment of second-line non-small-cell lung cancer
1Indiana University, Indianapolis, IN 46202, USA. nhanna@iupui.edu
Abstract:
Treatment with third-generation chemotherapy agents improves survival and quality of life of patients with non-small-cell lung cancer (NSCLC). Despite these favorable outcomes, most patients receiving front-line therapy experience disease progression. The availability of many new novel agents with activity in NSCLC has prompted investigators to explore second-line chemotherapy options. For many years, docetaxel was the only approved agent for the second-line treatment of NSCLC. More recently, the multi-targeted antifolate pemetrexed has demonstrated activity in patients previously treated with chemotherapy with locally advanced or metastatic NSCLC. The findings of a phase III trial comparing pemetrexed to docetaxel led to the regulatory approval of pemetrexed as monotherapy for the second-line treatment of NSCLC. Several other novel therapies, including molecular targeting agents such as erlotinib, are under development in clinical trials in patients with NSCLC. One of these trials has subsequently led to the approval of erlotinib as second- or third-line therapy in advanced NSCLC.
Insights
Third-generation chemotherapy improves outcomes for non-small-cell lung cancer (NSCLC) patients. Novel agents like pemetrexed and erlotinib offer new second-line treatment options after disease progression.
Area of Science:
- Medical Oncology
- Pharmacology
Background:
- Third-generation chemotherapy improves survival and quality of life in non-small-cell lung cancer (NSCLC).
- Most patients with NSCLC experience disease progression after front-line therapy.
- Limited second-line treatment options were available for NSCLC previously.
Purpose of the Study:
- To review novel agents for second-line treatment of NSCLC.
- To discuss the efficacy and approval of pemetrexed and erlotinib in NSCLC.
Main Methods:
- Review of clinical trial data and regulatory approvals.
- Comparison of pemetrexed and docetaxel in a phase III trial.
- Evaluation of molecular targeting agents in NSCLC.
Main Results:
- Pemetrexed demonstrated activity in patients previously treated with chemotherapy for advanced NSCLC.
- A phase III trial comparing pemetrexed to docetaxel led to pemetrexed's approval as monotherapy.
- Erlotinib has been approved for second- or third-line therapy in advanced NSCLC.
Conclusions:
- Novel agents like pemetrexed and erlotinib have expanded second-line treatment options for NSCLC.
- These agents offer improved outcomes for patients with advanced NSCLC.
- Ongoing research continues to explore new therapies for NSCLC.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
11:17Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers